AU2011244983A1 — Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
Assigned to Boehringer Ingelheim International GmbH · Expires 2011-11-24 · 14y expired
What this patent protects
C WRPorbKlDCC\KXG\197169..DOC-1I I/ 2011 The invention is directed to an extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix, the matrix comprising at least two water 5 swelling polymers, wherein one of said polymer…
USPTO Abstract
C WRPorbKlDCC\KXG\197169..DOC-1I I/ 2011 The invention is directed to an extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix, the matrix comprising at least two water 5 swelling polymers, wherein one of said polymers is pregelatinized starch, and wherein another one of said polymers is an anionic polymer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.